18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.

MLA

Harlos, C., et al. “18F-Fluorodeoxyglucose Positron-Emission Tomography for the Investigation of Malignancy in Patients with Suspected Paraneoplastic Neurologic Syndromes and Negative or Indeterminate Conventional Imaging: A Retrospective Analysis of the Ontario PET Access Program, with Systematic Review and Meta-Analysis.” Current Oncology, vol. 26, no. 4, Aug. 2019, pp. E458–65. EBSCOhost, https://doi.org/10.3747/co.26.4583.

APA

Harlos, C., Metser, U., Poon, R., MacCrostie, P., & Mason, W. (2019). 18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis. Current Oncology, 26(4), E458–E465. https://doi.org/10.3747/co.26.4583

Chicago

Harlos, C., U. Metser, R. Poon, P. MacCrostie, and W. Mason. 2019. “18F-Fluorodeoxyglucose Positron-Emission Tomography for the Investigation of Malignancy in Patients with Suspected Paraneoplastic Neurologic Syndromes and Negative or Indeterminate Conventional Imaging: A Retrospective Analysis of the Ontario PET Access Program, with Systematic Review and Meta-Analysis.” Current Oncology 26 (4): E458–65. doi:10.3747/co.26.4583.